Rhythm Biosciences (ASX:RHY) has secured a strategic partnership with CancerIQ, a US digital oncology platform, to drive the commercial adoption of its geneType cancer risk assessment technology.
The agreement provides Rhythm with immediate access to more than 65 US health systems and 345 clinics, including major networks like Mount Sinai and the University of Pittsburgh Medical Center.
By embedding geneType directly into CancerIQ's existing clinical workflows, Rhythm bypasses the need to build a direct US sales force, significantly reducing capital requirements and execution risk.
The integration allows healthcare providers to order geneType tests through an automated "ordering wizard" that populates patient data seamlessly.
Unlike traditional hereditary testing that focuses on rare mutations, geneType combines common genetic variants with clinical and lifestyle factors to provide a comprehensive baseline risk model.
CEO Dr. David Atkins noted that the partnership transforms the company's market entry by placing Rhythm at the exact point where clinical decisions are made daily.
The platform's structure supports recurring revenue as patients move through long-term cancer screening pathways.
CancerIQ CEO Feyi Ayodele added that the partnership reinforces their mission to scale genomics by providing a unified infrastructure for emerging precision diagnostics.
At the time of reporting, Rhythm Biosciences' share price was $0.15.